ProteoSign specifications
Information
| Unique identifier | OMICS_18441 |
|---|---|
| Name | ProteoSign |
| Interface | Web user interface |
| Restrictions to use | None |
| Input data | The input file(s) should be made out of merging multiple LC-MS/MS runs (fractionation, replication) of a single, possibly multiplexed, experiment and should not be the result of merging different or parallel experiments. |
| Input format | TXT |
| Programming languages | Javascript, PHP |
| Computer skills | Basic |
| Version | 1.0 |
| Stability | Stable |
| Maintained | Yes |
Maintainer
- person_outline Ioannis Iliopoulos <>
Publication for ProteoSign
2017 Nucleic Acids Res
PMCID: 5793730
PMID: 28520987
DOI: 10.1093/nar/gkx444
ProteoSign in publication
PMCID: 5875995
PMID: 29324674
DOI: 10.3390/metabo8010005
[…] that were differentially regulated on each side of the colon after calcitriol treatment. , we identified and quantified 6018 proteins at a 1% false discovery rate. volcano plots extracted from the proteosign platform from the triplicate uplc-ms/ms dataset plot the average change distribution between treated and untreated 2d cell culture. this data was plotted on a log2 scale on the x-axis […]
ProteoSign institution(s)
Medical School, Division of Basic Sciences, University of Crete, Heraklion, Greece; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, UK; Lawrence Berkeley National Labs, DOE Joint Genome Institute, Walnut Creek, CA, USA; Institute of Molecular Biology and Biotechnology, FORTH, Heraklion, Greece; Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX, USA
ProteoSign funding source(s)
Supported by Wellcome Trust [WT094296MA and EU-FP7 ‘Sybilla’ number 201106]; EU-FP7 project InnovCrete.
ProteoSign reviews
Be the first to review ProteoSign